{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:01:52Z","timestamp":1791345712647,"version":"4.3.1"},"reference-count":47,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,8,25]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CD160 is a human natural killer (NK)-cell\u2013activating receptor that is also expressed on T-cell subsets. In the present study, we examined 811 consecutive cases of B-cell lymphoproliferative disorders (B-LPDs), and demonstrated CD160 expression in 98% (590 of 600) of chronic lymphocytic leukemia (CLL) cases, 100% (32 of 32) of hairy cell leukemia (HCL) cases, 15% (5 of 34) of mantle cell lymphoma (MCL) in the leukemic phase, and 16% (23 of 145) of other B-LPD cases. CD160 transcript and protein were absent in the normal B-cell hierarchy, from stem cells, B-cell precursors, maturing B cells in the germinal center, and circulating B cells, including CD5+CD19+ B1 cells in umbilical cord. CD160 positivity was significantly higher in CLL and HCL in terms of percentage (65.9% and 67.8%, respectively, P &lt; .0001) and median fluorescence intensity (552 and 857, respectively, P &lt; .0001) compared with all other B-LPD cases. Lymph node CLL samples were also CD160+. Using the disease-specific expression of CD5, CD23, and CD160, a score of 3 characterized CLL (diagnostic odds ratio, 1430); a score of 0 excluded CLL, MCL, and HCL; and the CD23\/CD5 ratio differentiated CLL from leukemic CD23+ MCL. In the B-cell lineage, CD160 is a tumor-specific antigen known to mediate cellular activation signals in CLL, and is a novel target for therapeutic manipulation and monitoring of minimal residual disease.<\/jats:p>","DOI":"10.1182\/blood-2011-02-334326","type":"journal-article","created":{"date-parts":[[2011,6,29]],"date-time":"2011-06-29T09:28:54Z","timestamp":1309339734000},"page":"2174-2183","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":49,"title":["Differential and tumor-specific expression of CD160 in B-cell malignancies"],"prefix":"10.1182","volume":"118","author":[{"given":"Timothy W.","family":"Farren","sequence":"first","affiliation":[{"name":"Division of Haemato-Oncology and Immunophenotyping Section, Department of Haematology, Barts and The London National Health Service (NHS) Trust, London, United Kingdom;"},{"name":"Blizard Institute of Cell and Molecular Sciences, Queen Mary University of London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Giustiniani","sequence":"additional","affiliation":[{"name":"Laboratoire de Th\u00e9rapie Cellulaire, Institut Jean Godinot, Reims, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Ting","family":"Liu","sequence":"additional","affiliation":[{"name":"Blizard Institute of Cell and Molecular Sciences, Queen Mary University of London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris A.","family":"Tsitsikas","sequence":"additional","affiliation":[{"name":"Division of Haemato-Oncology and Immunophenotyping Section, Department of Haematology, Barts and The London National Health Service (NHS) Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion G.","family":"Macey","sequence":"additional","affiliation":[{"name":"Division of Haemato-Oncology and Immunophenotyping Section, Department of Haematology, Barts and The London National Health Service (NHS) Trust, London, United Kingdom;"},{"name":"Blizard Institute of Cell and Molecular Sciences, Queen Mary University of London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Cavenagh","sequence":"additional","affiliation":[{"name":"Division of Haemato-Oncology and Immunophenotyping Section, Department of Haematology, Barts and The London National Health Service (NHS) Trust, London, United Kingdom;"},{"name":"Centre for Haemato-Oncology, Barts Cancer Institute, Barts, and The London School of Medicine and Dentistry, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E.","family":"Oakervee","sequence":"additional","affiliation":[{"name":"Division of Haemato-Oncology and Immunophenotyping Section, Department of Haematology, Barts and The London National Health Service (NHS) Trust, London, United Kingdom;"},{"name":"Centre for Haemato-Oncology, Barts Cancer Institute, Barts, and The London School of Medicine and Dentistry, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taussig","sequence":"additional","affiliation":[{"name":"Centre for Haemato-Oncology, Barts Cancer Institute, Barts, and The London School of Medicine and Dentistry, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian C.","family":"Newland","sequence":"additional","affiliation":[{"name":"Division of Haemato-Oncology and Immunophenotyping Section, Department of Haematology, Barts and The London National Health Service (NHS) Trust, London, United Kingdom;"},{"name":"Blizard Institute of Cell and Molecular Sciences, Queen Mary University of London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Calaminici","sequence":"additional","affiliation":[{"name":"Department of Histopathology, Barts, and The London NHS Trust, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Bensussan","sequence":"additional","affiliation":[{"name":"Inserm U976 and University Denis Diderot, H\u00f4pital Saint-Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jenner","sequence":"additional","affiliation":[{"name":"Division of Haemato-Oncology and Immunophenotyping Section, Department of Haematology, Barts and The London National Health Service (NHS) Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Gribben","sequence":"additional","affiliation":[{"name":"Centre for Haemato-Oncology, Barts Cancer Institute, Barts, and The London School of Medicine and Dentistry, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir G.","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Division of Haemato-Oncology and Immunophenotyping Section, Department of Haematology, Barts and The London National Health Service (NHS) Trust, London, United Kingdom;"},{"name":"Blizard Institute of Cell and Molecular Sciences, Queen Mary University of London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111810084807200_B1","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1084\/jem.178.3.1121","article-title":"A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity.","volume":"178","author":"Ma\u00efza","year":"1993","journal-title":"J Exp Med"},{"issue":"20","key":"2019111810084807200_B2","doi-asserted-by":"crossref","first-page":"9427","DOI":"10.1073\/pnas.90.20.9427","article-title":"Significant enlargement of a specific subset of CD3+CD8+ peripheral blood leukocytes mediating cytotoxic T-lymphocyte activity during human immunodeficiency virus infection.","volume":"90","author":"Bensussan","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2019111810084807200_B3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nri1570","article-title":"MHC class I molecules and KIRs in human history, health and survival.","volume":"5","author":"Parham","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"2019111810084807200_B4","first-page":"71","article-title":"BY55 (CD160).","volume":"1","author":"Bensussan","year":"2000","journal-title":"Protein Reviews on the Web"},{"issue":"6","key":"2019111810084807200_B5","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.4049\/jimmunol.161.6.2780","article-title":"Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes.","volume":"161","author":"Anumanthan","year":"1998","journal-title":"J Immunol"},{"issue":"2","key":"2019111810084807200_B6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ni1554","article-title":"CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.","volume":"9","author":"Cai","year":"2008","journal-title":"Nat Immunol"},{"issue":"8","key":"2019111810084807200_B7","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1182\/blood-2005-12-019919","article-title":"Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells.","volume":"108","author":"Fons","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2019111810084807200_B8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.emboj.7600019","article-title":"Unravelling natural killer cell function: triggering and inhibitory human NK receptors.","volume":"23","author":"Moretta","year":"2004","journal-title":"EMBO J"},{"issue":"1","key":"2019111810084807200_B9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/35095564","article-title":"Natural killer cells, viruses and cancer.","volume":"1","author":"Cerwenka","year":"2001","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2019111810084807200_B10","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.4049\/jimmunol.162.3.1223","article-title":"Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells.","volume":"162","author":"Agrawal","year":"1999","journal-title":"J Immunol"},{"issue":"9","key":"2019111810084807200_B11","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.4049\/jimmunol.173.9.5349","article-title":"Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset.","volume":"173","author":"Barakonyi","year":"2004","journal-title":"J Immunol"},{"issue":"26","key":"2019111810084807200_B12","doi-asserted-by":"crossref","first-page":"16963","DOI":"10.1073\/pnas.012681099","article-title":"Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity.","volume":"99","author":"Le Bouteiller","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2019111810084807200_B13","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.4049\/jimmunol.167.4.1877","article-title":"Cutting edge: induction of IFN-gamma production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells.","volume":"167","author":"Rajagopalan","year":"2001","journal-title":"J Immunol"},{"issue":"4","key":"2019111810084807200_B14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/intimm\/dxm005","article-title":"CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment.","volume":"19","author":"Rabot","year":"2007","journal-title":"Int Immunol"},{"issue":"15","key":"2019111810084807200_B15","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1182\/blood-2009-08-239483","article-title":"CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia.","volume":"115","author":"Liu","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111810084807200_B16","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1084\/jem.194.11.1625","article-title":"Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells.","volume":"194","author":"Klein","year":"2001","journal-title":"J Exp Med"},{"issue":"11","key":"2019111810084807200_B17","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.194.11.1639","article-title":"Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.","volume":"194","author":"Rosenwald","year":"2001","journal-title":"J Exp Med"},{"issue":"4","key":"2019111810084807200_B18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0092-8674(92)90598-7","article-title":"ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain.","volume":"71","author":"Chan","year":"1992","journal-title":"Cell"},{"issue":"4","key":"2019111810084807200_B19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/path.1727","article-title":"Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms.","volume":"205","author":"Carreras","year":"2005","journal-title":"J Pathol"},{"issue":"4","key":"2019111810084807200_B20","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1309\/WVQPVDF8UF7AV21X","article-title":"ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL\/SLL.","volume":"122","author":"Sup","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"2019111810084807200_B21","first-page":"899","article-title":"ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells.","volume":"90","author":"Guillaume","year":"2005","journal-title":"Haematologica"},{"issue":"6","key":"2019111810084807200_B22","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/sj.leu.2403726","article-title":"ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype.","volume":"19","author":"Nolz","year":"2005","journal-title":"Leukemia"},{"issue":"4","key":"2019111810084807200_B23","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/sj.leu.2404138","article-title":"ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage.","volume":"20","author":"Scielzo","year":"2006","journal-title":"Leukemia"},{"issue":"12","key":"2019111810084807200_B24","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"2019111810084807200_B25","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"5","key":"2019111810084807200_B26","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1309\/XV4AG7EMWQU7ER67","article-title":"CD23 expression in mantle cell lymphoma: clinicopathologic features of 18 cases.","volume":"120","author":"Schlette","year":"2003","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"2019111810084807200_B27","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1309\/UQ4N-M5KL-0ANY-YD3G","article-title":"Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia\/small lymphocytic lymphoma.","volume":"116","author":"Gong","year":"2001","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"2019111810084807200_B28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-065X.2009.00783.x","article-title":"The CD160, BTLA, LIGHT\/HVEM pathway: a bidirectional switch regulating T-cell activation.","volume":"229","author":"Cai","year":"2009","journal-title":"Immunol Rev"},{"issue":"5","key":"2019111810084807200_B29","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/intimm\/14.5.445","article-title":"BY55\/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression.","volume":"14","author":"Nikolova","year":"2002","journal-title":"Int Immunol"},{"issue":"9","key":"2019111810084807200_B30","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1128\/MCB.16.9.5026","article-title":"Distinct tyrosine phosphorylation sites in ZAP-70 mediate activation and negative regulation of antigen receptor function.","volume":"16","author":"Kong","year":"1996","journal-title":"Mol Cell Biol"},{"issue":"7","key":"2019111810084807200_B31","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1084\/jem.189.7.1163","article-title":"ZAP-70 protein promotes tyrosine phosphorylation of T cell receptor signaling motifs (ITAMs) in immature CD4(+)8(+) thymocytes with limiting p56(lck).","volume":"189","author":"Ashe","year":"1999","journal-title":"J Exp Med"},{"issue":"13","key":"2019111810084807200_B32","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1182\/blood-2002-06-1683","article-title":"Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.","volume":"100","author":"Chen","year":"2002","journal-title":"Blood"},{"issue":"9","key":"2019111810084807200_B33","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/sj.leu.2401470","article-title":"Cyclin D1 overexpression allows identification of an aggressive subset of leukemic lymphoproliferative disorder.","volume":"13","author":"Levy","year":"1999","journal-title":"Leukemia"},{"issue":"9","key":"2019111810084807200_B34","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/sj.leu.2402200","article-title":"Atypical lymphocytic leukemia and mantle cell lymphoma immunologically very close: flow cytometric distinction by the use of CD20 and CD54 expression.","volume":"15","author":"Deneys","year":"2001","journal-title":"Leukemia"},{"issue":"3","key":"2019111810084807200_B35","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1046\/j.1365-2141.2003.04071.x","article-title":"Cell surface CD43 determination improves diagnostic precision in late B-cell diseases.","volume":"120","author":"Jung","year":"2003","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111810084807200_B36","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.leukres.2009.01.017","article-title":"CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia.","volume":"33","author":"Palumbo","year":"2009","journal-title":"Leuk Res"},{"issue":"3","key":"2019111810084807200_B37","first-page":"326","article-title":"Distinction between small lymphocytic and mantle cell lymphoma by immunoreactivity for CD23.","volume":"7","author":"Dorfman","year":"1994","journal-title":"Mod Pathol"},{"issue":"3","key":"2019111810084807200_B38","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12032-007-9038-7","article-title":"Analysis of CD23 antigen expression in B-chronic lymphocytic leukaemia and its correlation with clinical parameters.","volume":"25","author":"Jurisic","year":"2008","journal-title":"Med Oncol"},{"issue":"10","key":"2019111810084807200_B39","first-page":"1640","article-title":"The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL.","volume":"8","author":"Matutes","year":"1994","journal-title":"Leukemia"},{"issue":"4","key":"2019111810084807200_B40","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/ajcp\/108.4.378","article-title":"Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b).","volume":"108","author":"Moreau","year":"1997","journal-title":"Am J Clin Pathol"},{"issue":"22","key":"2019111810084807200_B41","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.","volume":"116","author":"Hudecek","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111810084807200_B42","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1073\/pnas.0510081103","article-title":"Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation.","volume":"103","author":"McWhirter","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111810084807200_B43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hon.948","article-title":"ROR1 expression is not a unique marker of CLL.","volume":"29","author":"Barna","year":"2011","journal-title":"Hematol Oncol"},{"issue":"7","key":"2019111810084807200_B44","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1080\/10428190802124000","article-title":"Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia.","volume":"49","author":"Shabani","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111810084807200_B45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1365-2567.2001.01163.x","article-title":"The unusual distribution of the neuronal\/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans.","volume":"102","author":"Wright","year":"2001","journal-title":"Immunology"},{"issue":"5","key":"2019111810084807200_B46","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1084\/jem.176.5.1319","article-title":"Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression.","volume":"176","author":"Dancescu","year":"1992","journal-title":"J Exp Med"},{"issue":"4","key":"2019111810084807200_B47","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1182\/blood-2004-08-3335","article-title":"HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia.","volume":"105","author":"N\u00fcckel","year":"2005","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/8\/2174\/1349185\/zh803411002174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/8\/2174\/1349185\/zh803411002174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T21:39:38Z","timestamp":1686173978000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/8\/2174\/29504\/Differential-and-tumorspecific-expression-of-CD160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,25]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-02-334326","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,25]]}}}